

Forschungsprojekte 2019

Projets de recherche 2019

Unterstützt von: / Soutenus par:

krebsforschung schweiz
 recherche suisse contre le cancer
 ricerca svizzera contro il cancro
 swiss cancer research

Grundlagenforschung / Recherche fondamentale			
<u>Gesuchsteller/In</u>	<u>Projektnummer</u> <u>Projekttitle</u>	<u>Dauer</u> <u>(Monate)</u>	<u>Betrag</u> <u>(CHF)</u>
<u>Candidat/e</u>	<u>Numéro du projet</u> <u>Titre du projet</u>	<u>Durée</u> <u>(mois)</u>	<u>Montant</u> <u>(CHF)</u>
Allam Ramanjaneyulu, Prof. Department of Clinical research / Haematology (Adults) Group University of Bern 3008 Bern	KFS 4896-08-2019 Investigating ribonuclease inhibitor (RNH1) mediated myelopoiesis to resolve myeloid differentiation blockade in myeloid malignancies	12	134 300.–
Barth Patrick, Prof. EPFL SV IBI-SV UPBARTH Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 4687-02-2019 Rewiring adenosine signalling to enhance engineered T-cell therapies	36	354 800.–
Basler Konrad, Prof. Institut für Molekulare Biologie Universität Zürich (UZH) 8057 Zürich	KFS 4835-08-2019 Elucidating the Toll pathway's role in cancer progression and metastases formation	36	334 900.–
Baumgartner Martin, PD Dr. Oncology University Children's Hospital Zurich 8008 Zurich	KFS 4853-08-2019 Restricting cell invasion and tumour expansion by combinatorial targeting of FGFR signalling in malignant paediatric tumours	36	366 900.–
Böttcher Steffen, Dr. Department of Medical Oncology and Hematology University Hospital Zurich (USZ) 8091 Zurich	KFS 4885-08-2019 Elucidating and harnessing the molecular mechanism of the dominant-negative effect of TP53 missense mutations in premalignancy and overt cancer	42	283 750.–
Briskin Cathrin, Prof. Dr. SV ISREC UPBRI Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 4738-02-2019 Different facets of estrogen receptor alpha (ER) signalling during ER+ breast carcinogenesis	36	375 000.–

Cascione Luciano , Dr. Bioinformatics Core Unit IOR Institute of Oncology Research 6500 Bellinzona	KFS 4713-02-2019 Ultra-conserved long non-coding RNAs in B-cell lymphoma	24	180 600.–
De Libero Gennaro , Prof. Biomedicine University of Basel 4031 Basel	KFS 4707-02-2019 A novel population of human MR1-restricted T-cells in anti-tumour immunity	36	374 800.–
Dotto Gian-Paolo , Prof. Dr med. Département de biochimie Université de Lausanne (UNIL) 1066 Epalinges	KFS 4709-02-2019 Androgen receptor signalling in melanoma development	36	361 750.–
Herrmann Inge , Prof. Dr. Mechanical and Process Engineering ETH Zurich 9014 St. Gallen	KFS 4868-08-2019 Rationally designed high-z metal oxides for precision radiotherapy	36	238 900.–
Hess Christoph , Prof. Departement Biomedizin (DBM) Universität Basel 4031 Basel	KFS 4729-02-2019 Kynurenine pathway activation during EBV infection of B-cells: molecular metabolism, immune modulation and development of lymphoproliferation	36	375 000.–
Ho Ping-Chih , Dr Fundamental Oncology Ludwig Center of Cancer Research at the University of Lausanne 1066 Epalinges	KFS 4865-08-2019 CD36-mediated metabolic adaptation supports metabolic fitness and epigenome required for intratumoural Tregs	48	323 450.–
Kovacs Werner , PD Dipl.-Ing. Dr. techn. Institute of Molecular Health Sciences ETH Zurich 8093 Zurich	KFS 4735-02-2019 Exploring the role of pexophagy and peroxisomal metabolism in clear cell renal cell carcinoma (ccRCC) tumourigenesis	36	243 900.–
Krämer Stefanie , Prof. Department Chemistry and Applied Biosciences / Institute of Pharmaceutical Sciences ETH Zurich 8093 Zurich	KFS 4900-08-2019 Assessing the immune state of the tumour and its microenvironment by imaging Legumain and CD80 by positron emission tomography (PET)	48	374 950.–
Lengerke Claudia , Prof. Dr. med. Clinic for Hematology and Department of Biomedicine University Hospital Basel 4031 Basel	KFS 4852-08-2019 An unrecognized protein function adds a novel perspective to SOX2 driven cancer	36	353 650.–

Ludewig Burkhard , Prof. Medizinisches Forschungszentrum Kantonsspital St. Gallen (KSSG) 9007 St. Gallen	KFS 4701-02-2019 Deciphering the molecular landscape of cancer-associated fibroblasts in pancreatic cancer at single cell resolution	24	245 300.–
Meylan Etienne , Prof. ISREC Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 4839-08-2019 Characterization of lamellar body-like organelles and leucine-rich repeat kinase 2 in lung adenocarcinoma	48	326 950.–
Mitsiadis Thimios , Prof. Institute of Oral Biology University of Zurich 8032 Zurich	KFS 4890-08-2019 Single-cell analysis of human head and neck squamous cell carcinoma: clonality, microenvironment, and cell-cell communication	36	367 450.–
Mueller Cristina , PD Dr. Center for Radiopharmaceutical Sciences ETH-PSI-USZ Paul Scherrer Institut (PSI) 5232 Villigen-PSI	KFS 4678-02-2019 Design and application of a new class of PSMA ligands in combination with terbium radioisotopes	36	350 800.–
Orts Julien , Dr Chemistry ETH Zurich 8093 Zurich	KFS 4903-08-2019 Structural investigation of the mechanism of inhibition of KRas by small molecules	42	284 950.–
Peng Ren-Wang , PD Dr. Universitätsklinik für Thoraxchirurgie Inselspital Bern 3010 Bern	KFS 4851-08-2019 Integrative molecular characterization uncovers new therapeutic rationales for malignant pleural mesothelioma (MPM)	36	374 450.–
Pertz Olivier , Prof. Institut für Zellbiologie Universität Bern 3012 Bern	KFS 4867-08-2019 Imaging breast cancer oncogenic signalling and its response to targeted therapy at the single cell level	36	368 700.–
Petrova Tatiana , Prof. Dr Department of Fundamental Oncology University of Lausanne (UNIL) 1066 Epalinges	KFS 4895-08-2019 Overcoming chemoresistance and immune exclusion in colorectal cancer	36	375 000.–
Platt Randall , Prof. Dr. Department of Biosystems Science and Engineering ETH Zurich 4058 Basel	KFS 4863-08-2019 Development of a high-throughput CRISPR- Cas9 in vivo platform for rapid modelling of human cancers and biomarker discovery	36	375 000.–
Riggi Nicolo , Prof. Department of Pathology Central University Hospital of Vaud (CHUV) 1011 Lausanne	KFS 4859-08-2019 An integrative model of oncogenic epigenetic drivers in human translocated sarcomas	36	369 800.–

<p>Sartori Alessandro A., Prof. Dr. Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR) Universität Zürich (UZH) 8057 Zürich</p>	<p>KFS 4702-02-2019 Towards novel inhibitors targeting homologous recombination: from innovative research tools to cancer therapy</p>	<p>48</p>	<p>328 000.–</p>
<p>Tolstonog Genrich, PD Dr. Department of Otorhinolaryngology and Head and Neck Surgery Central University Hospital of Vaud (CHUV) 1066 Epalinges</p>	<p>KFS 4726-02-2019 Lymphovascular invasion as a source of residual disease and a potential treatment target following surgery in head and neck cancer</p>	<p>36</p>	<p>332 600.–</p>
<p>Verdeil Gregory, Dr Oncologie fondamentale Université de Lausanne (UNIL) 1066 Epalinges</p>	<p>KFS 4840-08-2019 Identifying immune mechanisms in muscle invasive bladder cancer and improving current immunotherapy</p>	<p>36</p>	<p>370 100.–</p>

Klinische Forschung / Recherche clinique			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Afshar-Oromieh Ali , PD Dr. med. Nuclear Medicine Inselspital Bern 3010 Bern	KFS 4723-02-2019 Development of deep learning algorithms for detection, quantification and characterization of prostate cancer lesions in PSMA-ligand PET/CT	24	153 850.–
Bassani-Sternberg Michal , Dr Oncology Centre hospitalier universitaire vaudois (CHUV) 1066 Epalinges	KFS 4680-02-2019 Deciphering the antigenic landscape of immunologically 'hot' and 'cold' tumours for optimal design of personalized cancer immunotherapy	36	374 300.–
Bertoni Francesco , Prof. Dr. med. Institute of Oncology Research Università della Svizzera italiana 6500 Bellinzona	KFS 4727-02-2019 An integrated approach to identify the mechanism of resistance to copanlisib and venetoclax in marginal zone lymphoma	36	360 350.–
De Bock Katrien , Prof. Health Sciences and Technology ETH Zurich 8603 Schwerzenbach	KFS 4758-02-2019 Metabolic and neurodevelopmental programmes regulating angiogenesis and the neurovascular unit (NVU) in brain tumours	48	322 500.–
Grünberg Jürgen , Dr. Zentrum für Radiopharmazeutische Wissenschaften PSI-ETH-USZ Paul Scherrer Institut (PSI) 5232 Villigen PSI	KFS 4876-08-2019 Development of ovarian cancer stem cell-directed radioimmunotherapy using auger-electron and alpha-particle emitters	42	266 950.–
Huelsken Joerg , Prof. Dr. Faculté de sciences de la vie SV EPF de Lausanne 1015 Lausanne	KFS 4830-08-2019 Targeting cancer plasticity mechanisms for an enhanced efficacy of immunotherapy	36	375 000.–
Iezzi Giandomenica , PD Dr. med. Ente Ospedaliero Cantoale, Department of Surgery Università della Svizzera italiana 6500 Bellinzona	KFS 4751-02-2019 Role of bacteria-specific T-lymphocytes in immune responses against human colorectal cancer	36	374 650.–
Neidert Marian , Dr. Department of Neurosurgery University Hospital Zurich (USZ) 8091 Zurich	KFS 4754-02-2019 Dissecting the heterogeneity of T-cell antigens in glioblastoma – mapping natural HLA ligands and characterizing tumour-infiltrating lymphocytes	48	325 000.–

Pless Miklos , Prof. Dr. Medizinische Onkologie Kantonsspital Winterthur 8401 Winterthur	KFS 4821-08-2019 Influence of a home-based nutrition and exercise programme including an application for monitoring quality of life in cancer outpatients	36	310 600.–
Rossi Davide , Dr Lymphoma & Genomics Research Program IOR Institute of Oncology Research 6500 Bellinzona	KFS 4705-02-2019 Molecular subtypes of splenic marginal zone lymphoma	12	125 000.–
Seiler Roland , PD Dr. med. Department of Urology University of Bern 3010 Bern	KFS 4718-02-2019 Determining predictors of response to a combination of checkpoint inhibitors (anti-PD-L1 and anti-CTLA-4) by single-cell tumour profiling and monitoring of immune cell populations in liquid biopsies in bladder cancers within the NITIMIB trial	36	365 750.–
Theocharides Alexandre , PD Dr. med. Klinik für Medizinische Onkologie und Hämatologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 4875-08-2019 Linking function and genomics of myelofibrosis stem cells	48	357 000.–
Worni Mathias , Dr. Visceral Surgery and Medicine University of Bern 3010 Bern	KFS 4682-02-2019 A phase II study to assess efficacy, safety and immunologic response of irreversible electroporation (IRE) followed by checkpoint inhibition (nivolumab) in metastatic pancreatic cancer	24	126 900.–

Psychosoziale Forschung / Recherche psychosociale

Gesuchsteller/In	Projektnummer Projekttitle	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Biller-Andorno Nikola , Prof. Dr. med. Dr. phil. Institute of Biomedical Ethics and History of Medicine University Zurich (UZH) 8006 Zurich	KFS 4690-02-2019 Autonomy and relations. Investigating the role of shared decision-making in young haemato-oncological patients	30	181 150.–
Bondolfi Guido , Prof Psychiatry University of Geneva 1205 Geneva	KFS 4696-02-2019 Mindfulness-based cancer recovery© programme for patients living with a gynaecological cancer: a randomized controlled pilot study (SERENITY)	36	125 750.–
Leibundgut Kurt , Prof. Dr. Universitätsklinik für Kinderheilkunde Inselspital Bern 3010 Bern	KFS 4708-02-2019 Efficacy of physical training and cognitive training in children and adolescents after cancer – the brainfit-study	12	95 800.–

Epidemiologische Forschung / Recherche épidémiologie

Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Auer Reto , Prof. Dr. med. Berliner Institut für Hausarztmedizin Universität Bern 3012 Bern	KFS 4744-02-2019 Effects of electronic nicotine delivery systems (ENDS) for smoking cessation on cancer-related health outcomes: 12-, 24-months follow-up of the efficacy, safety and toxicology of ends (ESTxENDS) randomized controlled trial	36	372 300.–
Berezowska Sabina Anna , PD Dr. Institute of Pathology University of Bern 3008 Bern	KFS 4694-02-2019 Molecular epidemiology of lung cancer brain metastases	36	365 500.–
Bochud Murielle , Prof. Dr med. Département Epidémiologie et systèmes de santé (DESS) Unisanté - Centre universitaire de médecine générale et santé publique 1010 Lausanne	KFS 4722-02-2019 Dietary intake, overweight, and late effects development in childhood cancer survivors	36	359 450.–
Guseva Canu Irina , Prof. Research and education in Occupational Health Institut universitaire romand de Santé au Travail (IST) 1066 Epalinges	KFS 4699-02-2019 Examining cancers and labour indicators to assess the burden (ExCaLiBur)	36	226 800.–
Hemkens Lars , PD Dr. med. Department of Clinical Research University Hospital Basel 4031 Basel	KFS 4842-08-2019 Emerging trends and developments in cancer treatment innovation: expansion of the CEIT- cancer project (exCEIT)	24	233 500.–
Kaderli Reto Martin , Dr. med. Department of Visceral Surgery and Medicine Inselspital Bern 3010 Bern	KFS 4741-02-2019 Distant metastases and long-term survival after complete resection of neuroendocrine tumours of the appendix: an international multicentre study (SurvivApp)	36	329 500.–

Stipendien 2019

Bourses 2019

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Bögeholz Jan Lukas , Dr. med. Klinik und Poliklinik für Innere Medizin UniversitätsSpital Zürich (USZ) 8091 Zürich	BIL KFS 4733-02-2019 Discovery of minor histocompatibility antigens for post allogeneic blood stem cell transplantation immunotherapy Destination: Divisions of Oncology and Hematology, Department of Medicine, Stanford University, Stanford (USA)	24	104 000.–
Correia Dora , Dr. med. Radiation Oncology Inselspital Bern 3010 Bern	BIL KFS 4755-02-2019 Practice pattern impact in cancer outcome in the paediatric proton consortium registry prospective cohort Destination: Francis H. Burr Proton Therapy Center, Department of Radiation Oncology, Massachusetts General Hospital, Boston (USA)	18	98 750.–
De Paula Costa Monteiro Inês Department of Oncology Centre hospitalier universitaire vaudois (CHUV) 1012 Lausanne	MD-PhD 4819-06-2019 SAMW MD-PhD Stipendium / Engineering T- cell for adoptive cell transfer therapy of cancer Destination: Department of Oncology, Centre hospitalier universitaire vaudois (CHUV), Lausanne	36	191 553.–
Schmassmann Philip Department of Biomedicine University of Basel 4055 Basel	MD-PhD 4818-06-2019 SAMW MD-PhD Stipendium / Synergistic activation of microglia by targeting CD47 and siglecs Destination: Departments of Biomedicine and Neurosurgery, University of Basel	36	188 250.–

<p>Telarovic Irma Department of Radiation Oncology University Hospital Zurich (USZ) 8091 Zurich</p>	<p>MD-PhD 4820-06-2019 SAMW MD-PhD Stipendium / Radiotherapy treatment volume and its role for the tumour- oriented immune response</p> <p>Destination: Department of Radiation Oncology, University of Zurich</p>	<p>36</p>	<p>189 902.–</p>
<p>Wilk Christian Matthias, Dr. med. Department of Medial Oncology and Hematology University Hospital Zurich (USZ) 8091 Zurich</p>	<p>BIL KFS 4724-02-2019 ERK signalling pathway activity in dendritic cell development and disease</p> <p>Destination: Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York (USA)</p>	<p>12</p>	<p>52 000.–</p>